4.6 Review Book Chapter

Recent Advances in Nanoparticle-Mediated siRNA Delivery

期刊

出版社

ANNUAL REVIEWS
DOI: 10.1146/annurev-bioeng-071813-105119

关键词

siRNA delivery; nanoparticle; gene therapy; stability; intracellular trafficking

资金

  1. NCI NIH HHS [U54CA151838] Funding Source: Medline
  2. NHLBI NIH HHS [HL109442] Funding Source: Medline
  3. NIAID NIH HHS [AI096395] Funding Source: Medline
  4. NIBIB NIH HHS [EB015000, EB013274-01A1, EB015152] Funding Source: Medline
  5. NATIONAL CANCER INSTITUTE [U54CA151838] Funding Source: NIH RePORTER
  6. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL109442] Funding Source: NIH RePORTER
  7. NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R21EB015152, R21EB013274] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Inhibiting specific gene expression by short interfering RNA (siRNA) offers a new therapeutic strategy to tackle many diseases, including cancer, metabolic disorders, and viral infections, at the molecular level. The macromolecular and polar nature of siRNA hinders its cellular access to exert its effect. Nanoparticulate delivery systems can promote efficient intracellular delivery. Despite showing promise in many preclinical studies and potential in some clinical trials, siRNA has poor delivery efficiency, which continues to demand innovations, from carrier design to formulation, in order to overcome transport barriers. Previous findings for optimal plasmid DNA delivery cannot be generalized to siRNA delivery owing to significant discrepancy in size and subtle differences in chain flexibility between the two types of nucleic acids. In this review, we highlight the recent advances in improving the stability of siRNA nanoparticles, understanding their intracellular trafficking and release mechanisms, and applying judiciously the promising formulations to disease models.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据